These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 18326228

  • 1. [The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and diabetic nephropathy].
    Shamkhlova MSh, Trubitsyna NP, Katsaia GV, Goncharov NP, Malysheva NM, Il'in AV, Nikankina LV, Koshel' LV, Shestakova MV.
    Ter Arkh; 2008; 80(1):49-52. PubMed ID: 18326228
    [Abstract] [Full Text] [Related]

  • 2. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ, Jacobsen P, Rossing K, Boomsma F, Parving HH.
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [Abstract] [Full Text] [Related]

  • 3. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, van Gilst WH, Voors AA.
    Int J Cardiol; 2006 Jan 26; 106(3):367-72. PubMed ID: 16337046
    [Abstract] [Full Text] [Related]

  • 4. The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus.
    Price DA, De'Oliveira JM, Fisher ND, Williams GH, Hollenberg NK.
    Am J Hypertens; 1999 Apr 26; 12(4 Pt 1):348-55. PubMed ID: 10232494
    [Abstract] [Full Text] [Related]

  • 5. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 26; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 6. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy.
    Seki N, Hashimoto N, Suzuki Y, Yagui K, Saito Y.
    Diabetes Res Clin Pract; 2006 May 26; 72(2):135-41. PubMed ID: 16290123
    [Abstract] [Full Text] [Related]

  • 7. Should the use of short acting angiotensin-converting enzyme inhibitors be abandoned?
    Erman A, Boner G, van Dijk DJ.
    J Renin Angiotensin Aldosterone Syst; 2000 Dec 26; 1(4):365-8. PubMed ID: 11967825
    [Abstract] [Full Text] [Related]

  • 8. [Activity of renin-angiotensin-aldosterone system (RAAS) and vasopressin level in patients with primary pulmonary hypertension].
    Martyniuk TV, Chazova IE, Masenko VP, Volkov VN, Belenkov IuN.
    Ter Arkh; 1998 Dec 26; 70(4):33-6. PubMed ID: 9612899
    [Abstract] [Full Text] [Related]

  • 9. Increased aldosterone levels in a model of type 2 diabetes mellitus.
    Fredersdorf S, Endemann DH, Luchner A, Heitzmann D, Ulucan C, Birner C, Schmid P, Stoelcker B, Resch M, Muders F, Riegger GA, Weil J.
    Exp Clin Endocrinol Diabetes; 2009 Jan 26; 117(1):15-20. PubMed ID: 18726873
    [Abstract] [Full Text] [Related]

  • 10. Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
    Schjoedt KJ, Lajer M, Andersen S, Tarnow L, Rossing P, Parving HH.
    Scand J Clin Lab Invest; 2006 Jan 26; 66(3):173-80. PubMed ID: 16714246
    [Abstract] [Full Text] [Related]

  • 11. High levels of circulating interleukin-10 in diabetic nephropathy patients.
    Myśliwska J, Zorena K, Semetkowska-Jurkiewicz E, Rachoń D, Suchanek H, Myśliwski A.
    Eur Cytokine Netw; 2005 Jun 26; 16(2):117-22. PubMed ID: 15941682
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB, Britton ML.
    Pharmacotherapy; 2005 Nov 26; 25(11):1602-20. PubMed ID: 16232022
    [Abstract] [Full Text] [Related]

  • 13. Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes.
    Chuahirun T, Khanna A, Kimball K, Wesson DE.
    Am J Kidney Dis; 2003 Jan 26; 41(1):13-21. PubMed ID: 12500217
    [Abstract] [Full Text] [Related]

  • 14. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D.
    Semin Nephrol; 2007 Mar 26; 27(2):172-81. PubMed ID: 17418686
    [Abstract] [Full Text] [Related]

  • 15. [Level of angiotensin II and aldosterone in plasma is often elevated in patients with heart failure treated with converting enzyme inhibitors--preliminary results].
    Grzybowski J, Bilińska ZT, Janas J, Michalak E, Skwarek M, Ruzyłło W.
    Przegl Lek; 2002 Mar 26; 59(8):587-9. PubMed ID: 12638326
    [Abstract] [Full Text] [Related]

  • 16. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
    Navarro JF, Mora C, Muros M, García J.
    J Am Soc Nephrol; 2005 Jul 26; 16(7):2119-26. PubMed ID: 15917336
    [Abstract] [Full Text] [Related]

  • 17. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor.
    Ogawa S, Takeuchi K, Mori T, Nako K, Ito S.
    Clin Exp Pharmacol Physiol; 2006 Jul 26; 33(5-6):477-9. PubMed ID: 16700881
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin-converting enzyme inhibitors in diabetes: effect on the kidney and on blood pressure.
    Björck S, Aurell M.
    J Am Soc Nephrol; 1990 Nov 26; 1(5 Suppl 2):S59-63. PubMed ID: 16989067
    [Abstract] [Full Text] [Related]

  • 19. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F.
    J Hypertens; 2006 Nov 26; 24(11):2285-92. PubMed ID: 17053552
    [Abstract] [Full Text] [Related]

  • 20. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I, Stenehjem A, Høieggen A, Draganov B, Jenssen T, Holdaas H.
    Tidsskr Nor Laegeforen; 2002 Apr 10; 122(9):918-20. PubMed ID: 12082835
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.